Goodwin, Cooley Guide Septerna's Upsized $288M IPO
Clinical-stage drug developer Septerna Inc. is set to debut trading on Friday after pricing an upsized, $288 million initial public offering above its initial range, under guidance from Goodwin Procter LLP...To view the full article, register now.
Already a subscriber? Click here to view full article